Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARD1: ESK-001 in Moderate to Severe Plaque Psoriasis
jRCT2051240267Phase 3Completed
- Sponsor
- Alumis Inc.
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of envudeucitinib in plaque psoriasis (3 arms), sponsored by Alumis Inc. Primary endpoints: PASI 75 response at Week 16 and sPGA 0/1 at Week 16. Started Mar 2025; status: completed.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2051240267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240267.